{"news_desk": "Letters", "print_page": "22", "section_name": "Opinion", "subsection_name": null, "byline": [], "abstract": null, "type_of_material": "Letter", "word_count": "189", "lead_paragraph": "Jim Greenwood of the Biotechnology Industry Organization calls for an examination of &#8220;the insurance industry&#8217;s recent expansion of the use of specialty tier cost-sharing, in which patients must pay a relatively high percentage of their drug costs.&#8221;", "pub_date": "2015-05-12T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Cost Barrier to Medicines", "content_kicker": "Letter", "print_headline": "Cost Barrier to Medicines", "kicker": "Letter"}, "snippet": "Jim Greenwood of the Biotechnology Industry Organization calls for an examination of &#8220;the insurance industry&#8217;s recent expansion of the use of specialty tier cost-sharing, in which patients must pay a relatively high percentage of their...", "multimedia": [], "web_url": "http://www.nytimes.com/2015/05/12/opinion/cost-barrier-to-medicines.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Health Insurance and Managed Care", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Biotechnology Industry Organization", "name": "organizations"}], "blog": [], "_id": "5551a9e438f0d84851b12dce", "source": "The New York Times"}